



## **DNAe to Present New Data on LiDia™ BSI, its rapid blood-to-result diagnostic test at the Association of Molecular Pathology Annual Meeting**

**London, UK and Carlsbad, CA, USA – 7 November 2017** – DNAe, the inventor of semiconductor based genomic analysis technologies, and the developer of a new, game-changing test for bloodstream infections that can lead to sepsis will be presenting new data at the Association for Molecular Pathology (AMP) Annual Meeting 2017 in Salt Lake City, USA from the 16<sup>th</sup> to 18<sup>th</sup> November.

### **Poster Presentation – ID31**

**Title:** *Rapid Diagnosis of Bloodstream Infections Through Identification of Pathogens and Resistance Markers Directly from Whole Human Blood at 1 CFU/ml*

**Authors:** N. Casali, T. Mach, Z. Lang, F. Paillier, B.A. Brown, L-J. Clarizia, A. Bahrami, S. Barakat, N. Brown, M. Davila, A. Day, J. Gallagher, C. Icely, J. Killpack, S. McBader, G. McCabe, M. Norvell, S. Pradhan, N. Shublaq, A. Swanson, S. Tarver, N. Viswanathan, J.J. Ward, J. Wood, L. Xiong, C.J. McElgunn, R. Sahoo, D.W.N. Edington, D.A. Davidson, C. Toumazou

**Location:** Infectious Diseases Poster Session, Exhibit Hall

**Time:** 9:45 am – 10:45 am, Saturday, 18<sup>th</sup> November

Drs. Nicola Casali, Nour Shublaq and Francois Paillier will be available to discuss the data.

Dr Steve Allen, CEO of DNAe Group Holdings, commented: “As we move our LiDia™ BSI rapid blood-to-result diagnostic test towards commercial launch, we are pleased to present, for the second year running, key data at the AMP Annual Meeting, one of the premier annual gatherings in the field of molecular diagnostics. This is an exciting time for DNAe as we prepare to CE mark LiDia™ BSI in 2018, to enable us to bring this urgently needed test to market.”

—Ends—

### **About DNAe – [www.dnae.com](http://www.dnae.com)**

DNAe is commercializing its pioneering semiconductor DNA sequencing technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling the right treatment at the right time.

In January 2015 DNAe acquired nanoMR, Inc. (now DNA Electronics Inc.), a developer of a novel system for rapid isolation of rare cells in the bloodstream. DNAe is developing LiDia™, its sample-to-result genomic analysis platform, combining DNA Electronics Inc.’s Pathogen Capture System with its own portfolio of semiconductor-based genomic technologies, trademarked Genalysis®. The LiDia™ range of tests will enable DNA analysis directly on a microchip, providing rapid and accurate results from a user-friendly system.

DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. LiDia™ launches with the LiDia™ Bloodstream Infection (BSI) test, a groundbreaking rapid direct-from-specimen test for bloodstream infections that lead to sepsis. Built into a compact device for use at the point of need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease.

In October 2016, the Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS)

awarded DNAe a contract worth up to \$51.9 million to develop Genalysis® for rapid diagnosis in two key applications; antimicrobial resistant infections and pandemic influenza.

A private company, with bases in London, UK and Carlsbad, CA, USA, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting-edge life sciences companies.

## **Contact Details**

### **DNAe**

Dr Steve Allen, Chief Executive Officer, DNAe Group

Tel: +44 (0)20 7036 2100

### **Instinctif Partners (media relations)**

Sue Charles / Ashley Tapp / Alex Bannister

Tel: +44 (0)20 7457 2020

Email: [DNAe@instinctif.com](mailto:DNAe@instinctif.com)